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Coagulative abnormalities are a well-recognised feature of malignancy. The risk of 
developing thrombotic disorders is increased four-fold in cancer patients and more than 
six-fold higher in those receiving chemotherapy. Consequently, coagulative disorders are 
the second leading cause of death in cancer patients. One of the principal mechanisms 
through which cancer cells promote coagulation is through the upregulation of tissue 
factor (TF), a transmembrane receptor expressed on cells surrounding the blood vessels 
and a potent initiator of coagulation. Upon binding to circulating coagulation factor VIIa 
(FVIIa), TF and FVIIa form a catalytic complex, initiating the extrinsic coagulation 
pathway and resulting in the rapid formation of blood clots.  
 
Chimeric Antigen Receptor (CAR) T cell therapy is an emerging form of immunotherapy 
which combines the specificity of antibodies with the cytolytic activity of T cells, 
enabling potent killing of tumours in an antigen-antibody defined interaction. TF has 
been explored as a therapeutic target for a range of cancer treatments, however its 
potential as a target antigen for CAR T cell therapy is yet to be realised. The anti-TF 
monoclonal antibody, TF8-5G9, has been shown to effectively bind to and inhibit the 
procoagulant function of human TF making it an ideal candidate for a novel CAR 
structure. The efficacy of the construct would first need to be demonstrated in a pre-
clinical setting. However, human TF is highly efficient at complexing with murine FVIIa. 
Thus, expression of the antigen in a live model could result in major coagulopathies. 
 
This research tackles this issue by generating a truncated form of human TF, using 
inverse PCR, thereby deleting the FVIIa binding sites while disabling any TF-driven 
coagulation. Flow cytometric and western blot analyses showed that the expression of 
the truncated TF was mainly intracellular. However, no coagulation was triggered by the 
low-level surface expression of the truncated TF, as shown by our in vitro coagulation 
assay. Failure to efficiently export TF to the surface may be attributed to protein 
misfolding and thus demands different strategies to truncate the TF gene. Together, these 
results provide the model framework for TF as a novel target in immunotherapy.  
 
 iv 
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Cancer refers to a group of diseases characterised by the uncontrolled proliferation of 
abnormal cells with the potential to invade tissues [1]. Cells become transformed through 
the acquisition of genetic mutations or epigenetic changes in genes which regulate the 
cell cycle and promote malignancy [2]. Hereditary and environmental elements are both 
contributors to the causes of cancer, with the majority of cases stemming from the latter 
[3]. These include lifestyle factors such as tobacco use, diet and exercise, sun exposure, 
chronic inflammation and infection by oncogenic viruses [3]. Globally, cancer ranks 
among the top leading cause of deaths, estimated to develop in one in six people [4]. 
Standard treatment options include chemotherapy, radiation and/or surgery; however, 
these are most often not curative and pose a high risk of adverse side effects [5]. 
Researchers around the world are endeavouring to create new therapies which meet the 
demand for safer and more effective treatments.  
 
 The immune response and tumours 
The human immune system consists of two branches: the innate arm and the adaptive 
arm [6]. In general, the innate response is rapid, non-specific and does not confer lasting 
immunity [6]. In contrast, the adaptive arm is slower to respond but capable of generating 
specific immunological memory [6]. In response to infection, the innate arm clears 
foreign material by phagocytosis or apoptosis [7]. Innate leukocytes such as macrophages 
may engulf or release enzymes which destroy extracellular pathogens, while natural 
killer (NK) cells induce apoptosis in intracellularly infected or transformed malignant 
cells. Dendritic cells (DCs) and other members of the antigen-presenting cell (APC) 
family act as a bridge between the innate and adaptive arms [6, 7]. APCs sample native 
antigen and present processed peptides on major histocompatibility complex (MHC) 
molecules to cells of the adaptive immune system [6]. 
 
The two primary mediators of adaptive immunity are T and B lymphocytes [6]. The 
adaptive immune response is initiated when antigen-specific T cells encounter peptide 
bound to MHC, stimulating signalling through the T cell receptor (TCR; ref. [6, 8]). 
Additional costimulatory signalling through receptors such as cluster of differentiation 
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28 (CD28) is required to enable full activation of T cells [6]. T cells mediate diverse 
functions in the immune system and are broadly classed into helper, cytotoxic or 
regulatory subsets based on their differential expression of receptors, cytokines and 
transcriptional profiles [6]. B lymphocytes provide humoural immunity through the 
production of soluble immunoglobulin (Ig), also known as antibody [9]. Antibodies can 
directly neutralise pathogens or tag them for phagocytosis by innate leukocytes thus, have 
a crucial role in enhancing pathogen clearance [8, 10]. On naïve B cells, 
immunoglobulins exist as membrane bound receptors which recognise native antigens 
[8]. Antigen binding and cytokine activation signals provided by T helper cells stimulate 
B cell differentiation into antibody secreting plasma subsets, or memory subsets which 
persist long-term and rapidly expand upon re-exposure to specific antigens [6, 11].  
 
With regard to cancer, the anti-tumour immune response is primarily mediated by NK 
cells and cytotoxic T lymphocytes (CTLs; ref. [12]). Growing tumours may release 
inflammatory cytokines which recruit CTLs and NK cells to the tumour site [13]. 
Infiltrating CTLs engage MHC-tumour peptide complexes through their antigen-specific 
TCRs and in response, release molecules which kill and eliminate tumours. Tumour cells 
which evade immune attack enter an immune-mediated equilibrium phase in which 
genetic and epigenetic changes accumulate [13, 14]. During this phase, poorly 
immunogenic variants are selected for, sculpting tumours into genetically diverse, 
heterogeneous and immune-resistant clonal populations [13, 15]. Tumour cells exhibit a 
myriad of mechanisms which enable escape from host immune responses [5, 12]. These 
include downregulation of MHC, upregulation of immune checkpoint ligands and 
upregulation of suppressive cell subsets that limit CTL and NK cell activation [12, 13]. 
Cancer cells exploit these safety mechanisms, meant to protect against autoimmune 
reactivity, and suppress the immune response to favour survival [15, 16]. The complex, 
immunosuppressive network established by cancer poses a barrier to the natural host anti-
tumour immune response as well as potential immune-based treatments [12, 16, 17]. 
 
 Cancer immunotherapies and chimeric antigen receptor (CAR) T cells 
Immunological approaches to therapy aim to augment the natural host response against 
cancer cells [18]. Various immune-based strategies have gained traction over the years 
including cancer vaccines, immune checkpoint inhibitors and most recently, adoptive cell 
therapies (ACT; ref. [19]). As these treatments have gradually been introduced into the 
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clinic, interest has been sparked from both the public and cancer researchers alike as to 
whether these approaches can be more broadly generalised to treat all cancers.  
 
Despite considerable efforts, therapeutic cancer vaccines for the treatment of patients 
who have already developed cancer have found limited success over the years [20]. With 
the exception of Sipuleucel-T, an APC-based vaccine which targets prostate antigen, 
most vaccines have proven to be ineffective due to issues such as immune suppression 
by the tumour microenvironment and lack of unique tumour-associated antigens [20, 21]. 
Interestingly, phase I clinical trial data have rarely revealed immune-related toxicities, 
validating the relative safety of this approach. Hope remains that the efficacy of cancer 
vaccines can be improved with the use of adjuvants or by combination therapy with other 
anti-cancer treatments [20, 22].  
 
Perhaps the most well-known of the aforementioned immunotherapies are inhibitors of 
the immune checkpoints programmed cell death protein 1 (PD-1) and CTL-associated 
protein 4 (CTLA-4). Immune checkpoints function as negative regulators of T cell 
activation and are upregulated by activated T cells to limit autoimmunity [23, 24]. The 
inhibitory pathways stimulated by PD-1 activation are triggered by receptor binding to 
its ligands PD-L1 or PD-L2 [25]. These ligands are broadly expressed by immune cells 
and healthy tissues to limit excessive inflammatory responses that lead to autoimmune 
destruction of tissues and chronic inflammation [26]. However, tumour cells frequently 
exploit PD-1 activation on T cells as an escape mechanism, upregulating the inhibitory 
ligand PD-L1 to suppress the immune response against cancer [25]. The mechanism of 
the CTLA-4 checkpoint is distinct from this, preventing immune cell activation by 
attenuating the costimulatory signalling required for effective T cell responses [27]. 
CTLA-4 shares structural homology with the T cell costimulatory receptor CD28 and 
competes for binding to members of the B7 protein family on APCs. CTLA-4 displays a 
higher affinity for these ligands, thereby outcompeting CD28 for binding and resulting 
in reduced costimulatory signalling and T cell activation [28]. Since their inception, 
monoclonal antibodies which block these immune checkpoints to reengage the anti-
tumour response have proven strikingly effective, recently earning the two researchers 
behind concept the Nobel Prize in Physiology or Medicine for 2018 [29]. The FDA 
approved anti-PD-1 antibodies nivolumab and pembrolizumab are currently in clinical 
use for the treatment of advanced malignancies such as melanoma, non-small cell lung 
cancer and Hodgkin’s lymphoma to name a few [27, 30]. Clinical trial data of PD-1 
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blockade show long-lasting and clinically meaningful responses, translating into 
improved overall and progression-free survival in a subset of patients with advanced 
stage disease [31-34]. Similarly, the CTLA-4 antagonist ipilimumab, approved for the 
treatment of metastatic melanoma, has demonstrated reduced tumour progression and 
survival benefits both in patients with previously treated or untreated melanoma [35, 36]. 
Unfortunately, objective responses are infrequently observed therefore, the prolonged 
effects of treatment extend to only a small number of patients [32, 33, 37, 38]. Moreover, 
given that immune checkpoint inhibitors act to promote unrestrained T cell proliferation, 
use of these monoclonal antibodies has been associated with a high risk of immune-
related adverse events [32, 33, 35, 39]. Approximately 70-80% of patients experience 
side effects from treatment; however, most are low-grade and clinically manageable [39, 
40]. Immune checkpoint inhibitors are a clinical success story and mark a turning point 
in the way that cancer can be treated. Despite the remarkable ability of immune 
checkpoint inhibitors to extend survival and deliver durable and potentially curative 
effects, poor efficacy in the majority of patients as well as issues regarding safety warrant 
further investigation into alternative approaches in order to meet the needs of a broader 
range of patients.  
 
Another developing field of immunotherapy research is ACT which involves the 
administration of live, anti-tumour immune cells into a host [41, 42]. The biological 
approach to ACT involves treating patients with autologous tumour infiltrating 
lymphocytes; cells derived from resections of their own solid tumours and clonally 
expanded ex vivo [41, 42]. Preliminary findings from melanoma patients have been 
positive, with 40% of patients from all stages of disease exhibiting complete and durable 
regressions [43, 44]. Limiting the expansion of this therapy to other tumour types is 
accessibility to tumour infiltrating lymphocyte populations. Unlike melanoma, many 
epithelial-derived tumours cannot easily be excised therefore, sources from which 
tumour-specific cells can be derived are restricted. To overcome these limitations, 
researchers have extended the scope of ACT by applying genetic approaches that break 
the limitations of biology [45]. Chimeric antigen receptors (CAR), constructs designed 
to express on T cells and specifically target tumour-associated antigens, provide an 
engineered approach to ACT by offering an alternative means of generating tumour-




First proposed by Zelig Eshhar and colleagues in 1989, CARs are one of most recent 
additions to the toolbox of immunotherapy [46]. The basic CAR structure comprises 
three regions: the extracellular antigen recognition domain derived from single chain 
variable fragments (scFv) of antibodies, the transmembrane domain which anchors the 
protein to the cell surface and the intracellular domain consisting of T cell signalling 
components which enable activation of cytotoxic functions (Figure 1; ref. [47-49]). 
Direct recognition of native antigen can occur through the antibody-derived receptor, 
bypassing the need for MHC-restricted antigen peptide presentation which is usually 
downregulated in tumour environments [45, 50]. By this design, scFv can be selected to 
target any tumour-associated antigen desired, redirecting CARs T cells against a wide 
array of tumour antigens which may previously have been resistant to immune attack, 
while overcoming the complexities of MHC polymorphisms between patients. 
 
One of the biggest challenges in CAR T cell development is selection of an appropriate 
target antigen [22, 45, 50]. As most proteins expressed by tumours are also present on 
healthy cells, anti-tumour CARs can inadvertently attack self-tissue, resulting in severe 
off-tumour but on-target toxicities [43, 47]. Even minute expression levels by healthy 
cells can trigger full T cell activation and therefore, the ideal candidate protein is a surface 
antigen whose expression is fully restricted to tumour cells or non-vital cells [22, 51]. An 
antigen which closely meets these requirements is the B cell marker cluster of 
differentiation 19 (CD19), which has been a leading target of choice in early CAR T cell 
trials [45]. CD19 expression is a unique to B cells and is upregulated in most 
haematological malignancies including acute lymphoblastic leukaemia (ALL), chronic 
lymphocytic leukaemia and B cell lymphomas [52]. Targeting of tumours with second 
generation anti-CD19 CAR T cells has delivered remarkable response rates [53, 54]. One 
trial conducted by Maude and colleagues demonstrated complete remission in 90% of 
children and adults with relapsed or refractory ALL [53]. Of these patients, 70% had 
sustained remissions of up to two years which were associated with persistence of the 
reinfused cell subset. Results from this study demonstrated that engineered T cells 
populations could expand in vivo, have potent activity against advanced disease and 
persist long-term in hosts. While long-term effector functions are advantageous for 
eradicating larger tumour masses, the continued targeting of healthy CD19-expressing 
cells resulted in B cell aplasia in all patients who had a response. For most people, the 
effects of B cell aplasia are not life-threatening and can be clinically managed with 
intravenous Ig replacement therapy [45, 47]. Moreover, cytokine release syndrome 
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arising from infusional toxicities can be effectively controlled with interleukin 6-targeted 
therapies. Favourable outcomes seen from CD19 CAR trials highlight the therapeutic 
potential of immune cell engineering. Despite their success in haematological settings, 
application of CAR T cells to the solid tumour context has proven more challenging [47, 
51, 55-57]. Epithelial solid cancers account for 90% of all cancer-related deaths yet 
studies evaluating solid tumour antigens form the minority of CAR clinical trials [41, 
58]. As mentioned previously, expression of tumour antigen on healthy tissues creates 
specificity issues for solid tumour CARs [45, 50]. Immune attack of vital tissues has been 
the cause of multiple fatalities and as such, created valid concerns for patient safety in 
CAR trials going forward [59, 60]. Because few truly tumour-specific antigens exist, 
researchers are looking for other targets and features which discriminate normal from 







Figure 1: Prototypical structure of a chimeric antigen receptor (CAR). 
The basic CAR construct consists of an antigen recognition domain, derived from 
antibody fragments specific to tumour-associated antigen, spliced onto T cell signalling 
domains. When expressed on patient T cells, these engineered constructs redirect T cell 
cytotoxic functions with antibody-mediated specificity towards antigen-expressing 





 Overview of coagulation 
Haemostasis is the physiological response which maintains blood circulation and 
prevents bleeding (by clotting) upon injury to the vascular system [61]. This complex 
process is highly regulated by cellular and molecular components, which interact to 
promote procoagulant or anticoagulant functions at varying stages of the haemostatic 
process [62]. Under normal physiological conditions, coagulation factors circulate in the 
blood in their precursor states [61]. Damage to vessel walls exposes collagen, present 
within the endothelium, to the luminal contents resulting in adhesion of circulating 
platelets to endothelial collagen [63]. Contact between platelets and collagen fibres 
results in platelet activation, stimulating the release of dense granules which contain 
active factors that further promote the aggregation of platelets. A temporary platelet plug 
is formed at the site of injury to prevent bleeding and becomes moderately stabilised 
through the binding of fibrinogen in the blood to activated platelets [61, 64]. The plug 
becomes fully reinforced by the crosslinking of fibrin monomers, following conversion 
of fibrinogen to fibrin through the intrinsic and/or extrinsic coagulation cascade. 
 
The extrinsic pathway is triggered by the binding of two coagulation factors; 
active/inactive factor VII (FVIIa/FVII respectively) and tissue factor (TF; also known as 
FIII; ref. [65]). TF is a transmembrane receptor which provides haemostatic protection. 
Expression of TF is predominantly on the subendothelial cells surrounding blood vessels 
and on vital organs such as the brain, lungs and heart [66]. External trauma to vessel 
walls exposes TF to FVIIa circulating in the blood, forming a catalytic TF-FVIIa 
complex which activates other components of the cascade including FIX and FX [61, 
65]. The intrinsic pathway, also known as the TF-independent pathway, is engaged upon 
exposure of coagulation FXII to anionic/negatively charged surfaces such as endothelial 
collagen, exposed by vascular damage, or polyphosphates, released by activated platelets 
[61, 64]. In cascading fashion, activated FXII catalyses the activation of factor XI, which 
in turn activates FIX, which then finally activates FX [61, 64]. At FXa, the intrinsic and 
extrinsic pathways converge to form the common prothrombinase pathway [67]. 
Activated FX complexes with thrombin and FVa, forming the prothrombinase complex 
that cleaves prothrombin to thrombin [68, 69]. Thrombin catalyses the conversion from 




While it is known that TF is a potent initiator of coagulation, the majority of TF expressed 
in the body exists in a non-coagulant or cryptic form [70-72]. Mechanisms of TF 
decryption have yet to be elucidated; however, some theories suggest structural 
dissimilarities between non-coagulant / cryptic TF and procoagulant / decrypted TF [71]. 
There is variable evidence on whether cryptic TF exists in a dimerised or oligomerised 
state [70]. Conformational changes may expose a hidden binding cleft within the protein 
complex to enable binding to FX and conversion to the active decrypted state [71]. The 
mechanisms which support the conversion between encrypted and decrypted states may 
underlie the cause of some coagulation-related pathologies. 
 
 Tissue factor: a model antigen for anti-cancer immunotherapy 
Although coagulation is a vital physiological process, coagulative abnormalities feature 
prominently in malignancy [73-75]. Excessive coagulation can lead to thrombosis; the 
formation of clots within blood vessels that occlude blood flow [76]. The association 
between cancer and thrombosis, first characterised by Armand Trousseau in 1865, has 
now been made more evident with studies showing the risk of thrombotic events is 
increased four-fold in cancer patients and exacerbated to more than six-fold in those 
receiving chemotherapy [77-81]. Presently, thrombotic disorders are recognised as the 
second leading cause of death in cancer patients [82].  
 
At the centre of the relationship between cancer and thrombosis is TF-mediated 
coagulation. TF expression is often dysregulated in tumour cells resulting in aberrant 
upregulation, particularly in aggressive cancer types such as breast, melanoma and lung 
cancer [83-85]. Strikingly, the level of overexpression can be up to 105-fold that of non-
malignant tissues and is correlated with an increased risk of thrombosis [67]. Independent 
of TF-mediated hypercoagulation, signalling through the cytoplasmic domain of TF 
activates protease‐activated receptor 2 (PAR-2) pathways which function to promote 
tumour growth, metastasis, angiogenesis and inflammation [86, 87]. Given the clear role 
of TF in pathogenesis and mortality, targeting of TF represents a useful therapeutic 
option for anti-cancer therapy. 
 
Current anti-cancer therapies targeting TF include FVII-immunoconjugates, which bind 
to TF and induce antibody-mediated cytotoxicity, and photodynamic therapy which 
trafficks photosensitising drugs to TF-expressing tumours, allowing localised reactive 
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oxygen species to induce cell death upon light activation [86, 88, 89]. Direct injection of 
immunoconjugates was effective at reducing tumour volumes in a preclinical setting; 
however, these chimeric molecules exhibited procoagulant effects through TF-FVII 
binding, posing a high risk for thrombosis [88]. Studies of photodynamic therapy with 
TF-targeting nanoparticles showed successful localisation of photosensitising drugs to 
TF-overexpressing tumours [89]. Though photodynamic therapy is an attractive and 
minimally invasive approach, the activating light cannot penetrate deeply through skin, 
therefore application of this approach is limited to relatively superficial tumours. An 
alternate method of targeting TF is through the use of monoclonal antibodies. Screening 
of numerous TF-neutralising antibodies has revealed that the clone TF8-5G9 is the most 
effective inhibitor of TF procoagulant function [90, 91]. TF8-5G9 does not directly 
inhibit the binding of TF to FVIIa but instead neutralises the catalytic function of the TF-
FVIIa complex by binding and exerting steric hindrance, preventing complex interaction 
with subsequent coagulation factors in the cascade; FIX and FX [92]. In application with 
CAR technology, a TF8-5G9-derived CAR T cell could have substantial therapeutic 
potential. Exploiting the overexpression of TF as a target, an anti-TF TF8-5G9 CAR 
employed against tumours could mitigate increased thrombotic and metastatic risk whilst 
destroying TF-expressing cancer cells.  
 
The development of such a construct would firstly require refinement in a preclinical 
model. A study by Petersen et al. demonstrated that in vivo, human TF and murine TF 
have similar binding affinities to murine FVIIa, therefore both act as potent initiators of 
coagulation in mice [93]. Moreover, a tumour overexpressing the human TF in mice 
could result in excessive coagulative events. This is particularly problematic for 
experimental models which are administered directly into the bloodstream, such as the 
pulmonary metastatic tumour model [94]. In order to create a viable model, it would 
therefore be necessary to negate the procoagulant activity of TF. We propose that this 
limitation can be overcome by expressing a truncated form of the TF protein.  
 
Full-length TF is comprised of three domains: extracellular, transmembrane and 
cytoplasmic [95]. The extracellular domain consists of 219 amino acid residues which 
assemble into two protein modules: the membrane-associated carboxyl (C)-terminal 
module and the amino (N)-terminal module [95, 96]. These are separated by a disordered 
polypeptide linker at position 102-107 [97]. As shown in Figure 2, the binding epitope 
of FVIIa, resides predominantly in the N-terminal module. The most energetically 
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significant residues involved in this interaction have been identified as lysine-20, 
isoleucine-22 and phenylalanine-140 [98]. By contrast, the epitope for TF8-5G9 resides 
completely in the C-terminal module (Figure 2). In this research, we truncated TF at 
position 106 in the linker strand, removing the N-terminal module of the protein. Since 
FVIIa and TF8-5G9 binding regions are relatively distinct, truncation at the interdomain 
strand removes most of the sites involved in triggering coagulation while simultaneously 
retaining the epitope required for TF8-5G9 CAR T cell activation. For simplification, 
removal of the N-terminal module of TF will be referred to throughout this thesis as 
removal of FVII/FVIIa binding sites. In actuality, some residues involved in the binding 




Figure 2: Crystal structure of the extracellular domain of tissue factor (TF). 
Stick representation of the extracellular domain of human tissue factor (red). Protein 
orientation is with the C-terminus at the bottom of the image. (A) Residues involved in 
the interaction between TF to activated factor VII (FVIIa; yellow), reside predominantly 
in the N-terminal module. (B) Residues involved in the interaction between the anti-TF 
antibody TF8-5G9 to TF (blue) reside in the membrane-associated C-terminal module. 
Figure generated by PyMOL using the sequences from Huang et al., 1997 and Xie et al, 








 Aims and hypothesis 
Application of CAR T cell therapy to the solid tumour context is currently limited by a 
lack of appropriate targets. Since tumour antigens are generally derived from self-
proteins, on-target, off-tumour toxicities have been a common feature in clinical trials 
[47, 51, 55-57]. In this regard, the overexpression of TF on cancer cells presents a novel 
means of distinguishing malignant from non-malignant cells. TF is a relevant molecule 
in cancer and coagulation and warrants exploration as a potential therapeutic target. In 
this research, we aim to: 
1. Create a truncated form of the TF antigen  
2. Demonstrate surface expression of TF on a murine TF-negative cell line, 
detectable by TF8-5G9 antibody 
3. Compare the coagulative function of the truncated TF to full-length TF  
4. Develop a luciferase-based cytotoxicity assay for future testing with TF8-5G9 
CAR T cells 
We hypothesise that truncated TF will be capable of surface expressing on murine cancer 
cells, disarmed of its coagulative function and sufficiently antigenic to induce CAR T 
cell activation.   
 
Chapter Two:  




2.0 Methods and Materials 
 
2.1 Media and solutions 
2.1.1 RPMI-1640 Medium 
For 1 L: 1 × RPMI-1640 Medium sachet (Gibco #31800-022) 
 2 g of sodium bicarbonate 
 10 mL Penicillin / Streptomycin (100 U/mL / 100 µg/mL; Gibco 
#15140) 
55 µM β-mercaptoethanol (Gibco #21985) 
Total volume of 1 L made up using milliQ water 
 pH 7.3 
Filter sterilised (0.22 µm pore filters; Cole-Parmer® #EW-02915-52) 
 
2.1.2 RPMI-1640 + Foetal Calf Serum (FCS) 
R5: 95% RPMI-1640 medium 
 5% FCS (Pan Biotech #P30-3312) 
R10: 90% RPMI-1640 medium 
 10% FCS  
 
2.1.3 Dulbecco’s Phosphate Buffered Saline (PBS) 
For 1 L: 1 × PBS sachet (Gibco #21600-010) 
 Total volume of 1 L was made up using milliQ water 
 pH 7.3 
 Filter sterilised (0.22 µm pore filters) 
 
2.1.4 Bovine serum albumin (10% BSA; in PBS) 
For 100 mL: 10 g of BSA (Gibco # 30063-572) 
 Total volume made up to 100 mL using PBS 
 Filter sterilised (0.22 µm pore filters) 
 
 
2.1.5 Luria-Bertani Medium (LB) 
For 1 L: 10 g of Bacto™ Tryptone, Enzymatic digest of casein (BD #211705) 
 5 g of Bacto™ Yeast extract (BD #212750) 
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 5 g of NaCl (Scharlau #SO0227) 
 Total volume of 1 L was made up using milliQ water 
 
2.1.6 50× Tris-acetate-EDTA Buffer (TAE) 
For 1 L: 272 g of Tris 
 57 mL of glacial acetic acid 
 100 mL of 0.5 M EDTA pH 8.0 
 Total volume of 1 L was made up using milliQ water 
 pH 8.0 with NaOH 
 
2.1.7 2´ Ammonium sulphate [(NH4)2SO4] buffer 
150 mM Tris-HCl pH 8.8 
 40 mM (NH4)2SO4 
 0.02% Tween20 
 
2.1.8 2´ Polymerase chain reaction (PCR) master mix 
 2´ (NH4)2SO4 buffer 
 4 mM MgCl2 
 0.05 U/µL Taq polymerase (Thermo Scientific #EP0402) 
 0.4 mM dNTP (NEB #N0477L) 
 Total volume was made up using milliQ water 
 
2.1.9 Resazurin 
 0.12 g/L resazurin (Sigma-Aldrich # R7017-1G) 
 0.01 g/L methylene blue 
 0.1 M phosphate buffer 
 0.4 mM potassium ferricyanide 
 0.4 mM potassium ferrocyanide 
 pH 7.4 
 
2.1.10 Cell lysis buffer 
 0.02% azide 
 150 mM NaCl 
 0.25% CHAPS detergent 
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 0.5% Triton-X100 
 100 mM Tris 
 pH 8.0 
 cOmpleteÔ protease inhibitor (1 tablet / 10 mL; Roche  
 #11-697-498-001) 
 
2.1.11 Western blot reagents 
 4´ Bolt LDS Sample Buffer (Invitrogen #B0007) 
 10´ Bolt Sample Reducing Agent (Invitrogen #B0009) 
 Bolt 4-12% Bis-Tris Plus gels (Invitrogen #NW04120BOX) 
 Bolt MOPS SDS Running Buffer (Invitrogen #B000102) 
 Bolt Antioxidant (Invitrogen #BT0005) 
 SeeBlue Plus2 Pre-stained Protein Standard (Invitrogen #LC5925) 
 Nitrocellulose membrane (GE Healthcare #GE10600018) 
 Bolt Transfer Buffer (Invitrogen #BT0006) 
 
2.1.12 Flow cytometry fixation buffer 
 1% paraformaldehyde (PFA) 
 1% BSA/PBS 
 0.02% azide 
 Total volume was made up using PBS 
 
2.1.13 Permeabilisation buffer 
 0.2% Tween20 
 1% BSA 
 0.02% azide 
 5% FCS 




2.1.14 Coagulation-specific reagents 
 Human thrombin (Sigma #T-6884)  
 Human citrated platelet-poor plasma (PPP; Siemens #ORKL17) 
 Coagulation FVII-deficient PPP (Siemens #OTXV13) 




2.2 Restriction enzymes 
Table 2.1 List of restriction enzymes used in experiments 
Enzyme Reaction buffer Incubation Inactivation 
AccI (New England Biolabs; 
NEB #R0161S) 
Cutsmart®  
 (NEB #B7204S) 
37°C, 15 minutes 80°C, 20 minutes 
BsmBI (NEB #R0580S) 
NEBuffer 3.1  
(NEB #B7203S) 
55°C, 15 minutes 80°C, 20 minutes 
DpnI (NEB #R0176S) Cutsmart® 37°C, overnight 80°C, 20 minutes 
SfiI (NEB #R0123S) Cutsmart® 15°C, 15 minutes - 
 
2.3 Primer sequences 
Table 2.2 List of primer sequences used in experiments 
Primer pairs 5¢ – 3¢ sequence 

















Table 2.3 List of antibodies used in experiments 
 
2.5 Plasmids 
Table 2.4 List of plasmids made for experiments 
Plasmid Backbone Gene Notes 
pSBbi-RP:TF pSBbi-RP [101] 




SfiI-SfiI insertion of 
gBlock (encoding amino 
acids 1-263; 
NM_001993.4) 
pSBbi-RP:DTF pSBbi-RP D1-106huTF (IDT) 
SfiI-SfiI insertion of 
gBlock (encoding amino 
acids 107-263; 
NM_001993.4) 
pSBbi-RP:DTF-I pSBbi-RP:TF D1-106huTF 
Deletion of amino acids  
1-106 by IPCR 
pSBbi-BsmBI:TF pSBbi-BsmBI huTF (IDT) 
BsmBI-BsmBI insertion of 
gene (encoding amino acids 
1-263; NM_001993.4) 
pSBbi-BsmBI:TF+luc pSBbi-BsmBI:TF Luciferase (IDT) 
SfiI-SfiI insertion of 
gBlock encoding amino 
acids 1-550; AHC94771.1) 
 
Antibody Conjugation Clone Isotype Source 
Anti-human TF  - TF8-5G9 Mouse IgG1κ Purified in-house 
Anti-mouse IgG 
Alexa Fluor 488 
(AF488) 
- Goat IgG Invitrogen #A-11029 
Anti-mouse b-actin - AC-15 Mouse IgG1 Sigma #A1978 
Anti-mouse IgG 
Alexa Fluor 680 
(AF680) 
- Donkey IgG Invitrogen #SA5-10170 





2.6 Tumour cell lines 
Table 2.5 List of tumour cell lines used in experiments 
Cell line Disease Tissue Organism Notes 
EL4 Lymphoma T cells Murine (C57BL/6) ATCC #TIB-39 
EL4-TF Lymphoma T cells Murine (C57BL/6) 
EL4 transfected with 
pSBbi-RP:TF 
EL4-ΔTF Lymphoma T cells Murine (C57BL/6) 
EL4 transfected with 
pSBbi-RP:DTF 
EL4-ΔTF-I Lymphoma T cells Murine (C57BL/6) 






2.8 Restriction enzyme digest and dephosphorylation 
gBlocks (IDT) or plasmid pSBbi-RP were first reconstituted at 10 ng/µL with sterile 
milliQ or 100 ng/µL in TE buffer (pH 8.0) respectively. All restriction enzyme digests 
were performed as per the manufacturer’s instructions. In brief, 200 ng of gBlock DNA 
or 2 µg of vector DNA (30 µL or 50 µL reaction volume respectively) was digested with 
10 U of SfiI enzyme or 10 U of BsmBI enzyme (see Table 2.1 for conditions). Following 
digestion, vector DNA was dephosphorylated using 4 U of shrimp alkaline phosphatase 
(rSAP; NEB #M03715) and incubated at 30°C for 30 minutes then at 65°C for 5 minutes 
to heat inactivate the enzyme.  
 
2.9 DNA purification 
Digested DNA fragments were purified using the Monarch PCR & DNA Cleanup Kit 
(NEB #T10305) as per the manufacturer’s instructions. In brief, the samples were diluted 
in a 5:1 ratio of “DNA Cleanup Binding Buffer”, loaded onto a filter column and 
centrifuged at 16,000 ×g for one minute. The DNA was washed twice by adding 200 µL 
of “DNA Wash Buffer” to the column prior to centrifugation at 16,000 ×g for one minute. 
The sample was eluted by adding 15 µL of warm “DNA Elution Buffer” to the centre of 
the filter, incubating for one minute at room temperature, then centrifuged at 16,000 ×g 
for one minute. The DNA concentration of the sample was quantified using the Nanodrop 
ND-1000 instrument at 260 nm. 
 
2.10 Gel electrophoresis 
DNA samples (15 µL) were stained with 3 µL of DNA Loading Dye (Thermo Fisher 
Scientific #R0611) and 15-20 µL of sample was loaded into a 1% agarose gel consisting 
of 1% SeaKem LE agarose (Lonza #50004), TAE buffer and 1× SYBR Safe DNA Gel 
Stain (Invitrogen #S33102). The size of DNA fragments was referenced against the 
Quick-Load Purple 2-log DNA ladder (NEB #N05505). Gel electrophoreses were run at 
100 V, 300 mA for 60 min then imaged using the LiCor Biosciences Odyssey Fc 




2.11 Extraction of DNA from agarose gel 
DNA was extracted and purified from agarose gels using the Monarch DNA Gel 
Extraction Kit (NEB #T10205) as per manufacturer’s guidelines. In brief, DNA bands 
were excised from agarose gels using a scalpel, weighed, then dissolved in 4× volumes 
of “Gel Dissolving Buffer”. Gel slices were incubated at 50°C and vortexed occasionally. 
Once completely dissolved, the sample was loaded onto a filter column and centrifuged 
at 16,000 ×g for one minute. The DNA was washed twice by adding 200 µL of “DNA 
Wash Buffer” to the column and centrifuged at 16,000 ×g for one minute. The sample 
was eluted by adding 15 µL of warm “DNA Elution Buffer” to the centre of the filter, 
incubating for one minute at room temperature, then centrifuged at 16,000 ×g for one 
minute. The DNA concentration of the sample was quantified using the Nanodrop ND-
1000 instrument at 260 nm. 
 
2.12 DNA ligation 
Restriction enzyme-digested plasmids and gBlock inserts were ligated using T4 DNA 
Ligase (NEB #M0202S) according to the manufacturer’s instructions. In brief, a molar 
ratio of 3:1 of insert to vector DNA (90 ng:30 ng respectively) was supplemented with 
400 U (1 µL) of T4 DNA Ligase, 2 µL of T4 DNA Ligase Reaction Buffer (NEB 
#M0202S) and milliQ water to make up a total volume of 20 µL. The reaction mixture 
was incubated at 16°C overnight prior to heat inactivation of the ligase at 65º for 10 min. 
The ligated DNA was then used to transform bacteria (section 2.14).   
 
2.13 Calcium chloride (CaCl2) competent Escherichia coli 
LB media (2 mL) was inoculated with a colony of E. coli TOP10 and incubated overnight 
at 37°C with shaking at 200 rpm. The starter culture was added to 200 mL of LB media 
and incubated at 37°C with shaking at 200 rpm until an approximate OD600nm of 0.35-
0.45 was reached. The large culture was incubated in an ice water bath for 20 min then 
centrifuged at 2,000 ´g and 4°C for 10 min. The pelleted bacteria were resuspended in 
20 mL of pre-cooled 75 mM CaCl2/10 mM 1,4-Piperazinediethanesulfonic acid 
(PIPES)/15% glycerol, incubated in an ice bath for 20 min then centrifuged as previously 
mentioned. The bacterial pellet was resuspended in 2 mL of pre-cooled 
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CaCl2/PIPES/glycerol solution then aliquoted into microfuge tubes (pre-cooled to -80°C) 
and stored at -80°C.  
 
2.14 Transformation of CaCl2 competent E. coli 
All 20 µL of ligated DNA was added to 50 µL of thawed CaCl2 competent E. coli 
(sections 2.12 and 2.13), gently mixed by pipetting and incubated on ice for 30 min. The 
bacteria were then heat shocked at 42°C for 90 s and immediately plunged into ice for 
five minutes. To regenerate the transformed bacteria, the sample was added to 1 mL of 
pre-warmed LB media (37°C) and incubated at 37°C for one hour. A 100 µL and 900 µL 
aliquot of regenerated bacteria were plated on LB agar plates containing 100 µg/mL of 
ampicillin (AppliChem #A0839,0025) and incubated overnight at 37°C, 1% CO2.  
 
2.15 Colony PCR  
Transformed E. coli TOP10 bacterial colonies were touched with a sterile pipette tip, 
streaked onto a LB agar plate containing ampicillin (100 µg/mL) then incubated 
overnight at 37°C, 1% CO2. The remaining bacteria on the pipette tip were resuspended 
in 15 µL of a PCR solution containing 250 nM of each respective forward primer and 
reverse primer (Table 2.2) and sterile milliQ water as a diluent. The parameters used for 
colony PCR were: 95°C for two minutes; 35 cycles of 95°C for 30 s, 50°C for 30 s, 72°C 
for one minute per kb; 72°C for five minutes. PCR products were gel electrophoresed on 
a 1% agarose gel containing 1× SYBR Safe DNA Gel Stain and visualised using the 
LiCor Biosciences Odyssey Fc instrument at 600 nm. 
 
2.16 Miniprep plasmid purification 
Transformed E. coli TOP10 bacterial colonies were touched with a sterile loop, 
inoculated in 10 mL of LB broth with ampicillin (100 µg/mL) and grown overnight in a 
shaking incubator at 37°C, 200 rpm. Plasmids (Table 2.4) were purified from bacteria 
using the Monarch Plasmid Miniprep Kit (NEB # T1010L) in accordance with the 
manufacturer’s instructions. In brief, overnight bacterial cultures were first pelleted at 
6000 ×g for 15 min at 4ºC then resuspended in 200 µL of “Plasmid Resuspension Buffer”. 
Cells were then lysed using 200 µL of “Plasmid Lysis Buffer”, gently inverting the 
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suspension until a uniform colour was achieved prior to incubation at room temperature 
for one minute. The lysate was then neutralised using 400 µL of “Plasmid Neutralisation 
Buffer”, gently inverting the suspension until a precipitate was formed and a uniform 
colour was achieved prior to incubation at room temperature for two minutes. The lysate 
was then centrifuged at 16,000 ´g for at least five minutes until the pellet was compact. 
The supernatant was then transferred to a filter column and spun for one minute. DNA 
was then washed by using 200 µL of “Plasmid Wash Buffer 1” followed by 400 µL of 
“Plasmid Wash Buffer 2”, with a one-minute 16,000 ´g centrifugation between each 
wash. Plasmid DNA was then eluted by adding 40 µL of pre-warmed “DNA Elution 
Buffer” to the centre of the filter, incubated for one minute at room temperature, then 
centrifuged at 16,000 ×g for one minute. The DNA concentration of the sample was 
quantified using the Nanodrop ND-1000 instrument at 260 nm. 
 
2.17 Midiprep plasmid purification 
Transformed E. coli TOP10 bacterial colonies were touched with a sterile loop, 
inoculated in 150 mL of LB broth with ampicillin (100 µg/mL) and grown for 12-16 h in 
a shaking incubator at 37°C, 200 rpm. Plasmids (Table 2.4) were purified from bacteria 
using the NucleoBond Xtra Midi Plus kit (Macherey-Nagel #740412.50) as per the 
manufacturer’s instructions. In brief, bacterial starter cultures were pelleted at 6000 ´g 
for 15 min at 4°C then resuspended in 8 mL of “Resuspension Buffer RES + RNase A”. 
Cells were then lysed by adding the equivalent volume (8 mL) of “Lysis Buffer LYS” 
and gently inverting the suspension five times prior to incubation at room temperature 
for five minutes. The lysate was neutralised by adding an equivalent volume (8 mL) of 
“Neutralisation Buffer NEU” and gently inverting the tube until the suspension turned 
colourless. This suspension was loaded into a column filter, pre-equilibrated with 12 mL 
of “Equilibration Buffer EQU” and filtered by gravity flow to clarify the lysate and 
remove precipitate. The filter was then washed with 5 mL of “Equilibration Buffer EQU” 
and discarded, leaving the DNA in the remaining column. Plasmid DNA was washed by 
adding 8 mL of “Wash Buffer WASH” and eluted using 5 mL of pre-warmed “Elution 
Buffer ELU”. The eluted plasmid was precipitated by adding 3.5 mL of isopropanol, 
vortexed then incubated for two minutes at room temperature. The precipitation solution 
was loaded into a “NucleoBond Finalizer” and washed with 2 mL of 70% ethanol. The 
Finalizer containing the DNA pellet was dried, to remove ethanol, and the plasmid was 
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finally eluted with 600 µL of “Redissolving Buffer TRIS”. Eluted DNA concentration 
was quantified using the Nanodrop ND-1000 instrument at 260 nm. 
 
2.18 Cell culture 
EL4 (Table 2.5) cells stored in liquid nitrogen were thawed in R10 media (pre-warmed 
to 37°C) then centrifuged at 453 ´g for five minutes. Pellet was resuspended in 10 mL 
of R10 media, transferred to a 75cm2 cell culture flask and incubated at 37°C, 5% CO2. 
Cells were maintained at an approximate concentration of 1 ´ 106 cells/mL. 
 
2.19 Electroporation using the Neon transfection system 
EL4 cells were transfected with plasmid DNA using the Neon Transfection System 
(Invitrogen #MPK10025) according to the manufacturer’s instructions. In brief, cells 
were washed once in PBS then resuspended at 2 ´ 107 cells/mL in “Resuspension Buffer 
R”. Resuspended cells (110 µL), 1 µg of transposase DNA (SB100X) and 9 µg of plasmid 
DNA were combined in a microfuge tube and 100 µL of the mix was added to the Neon 
Tube (pre-filled with 3 mL of Electrolytic Buffer) for electroporation. EL4 cells were 
then electroporated with one pulse at 1080 V for 50 ms and immediately transferred to a 
6-well plate containing 4 mL of pre-warmed R10.  
 
2.20 Puromycin selection 
To determine the optimal concentration at which puromycin inhibits the growth of 
untransfected EL4 cells, a resazurin cell viability assay was performed. Puromycin 
(InvivoGen #ant-pr-5) was added to a 96-well flat-bottom plate (Thermo Fisher) in a 2-
fold serial dilution with R5 from 16,000 ng/mL to 15.625 ng/mL (50 µL/well). EL4 cells 
were resuspended in R5 at 2 ´ 105 cells/mL and 50 µL of cells were added to each well 
resulting in a total maximal concentration of 8,000 ng/mL of puromycin and 1 ´ 105 
cells/mL. The plate was incubated for 68 hours at 37°C, 5% CO2 before 10% resazurin 
(11 µL) was added to each well. The plate was incubated for a further four hours then 
fluorescence was measured using a microplate reader (Varioskan LUX; Thermo Fisher 




2.21 Fluorescence microscopy 
Cells (in 200 uL of R5) were first mounted on glass slides and incubated at 37°C with 
5% CO2 for 30 min in a humid box. A cover slip was then placed on the slides and 
visualised using an Olympus BX-51 upright microscope. Bright-field images were 
captured with an approximate shutter speed of 5 ms, while the red fluorescent protein 
(RFP) dTomato was visualised with a mercury/xenon lamp with an approximate shutter 
speed of 400 ms at 200´ magnification. 
 
2.22 Site-directed mutagenesis by inverse polymerase chain reaction (IPCR) 
The pSBbi-RP:TF plasmid (Table 2.4) was mutated by IPCR to generate a plasmid 
containing a truncated form of the human TF gene (pSBbi-RP:DTF-I). pSBbi-RP:TF 
template DNA (30 ng) was added to 0.5 µM of IPCR forward and reverse primers 
respectively (Table 2.2), 200 µM of dNTPs (NEB #N0447S), 0.02 U/µL of Q5 High-
fidelity DNA polymerase (NEB #M0491S), 5 µL of 5´ Q5 High GC enhancer (NEB 
#B9028S) , 5 µL of 5´ Q5 Reaction Buffer (NEB #B9027S) and nuclease free water was 
supplemented to a total volume of 25 µL. The parameters used for IPCR were: 98°C for 
30 s; 30 cycles of 98°C for 10 s, 65°C for one minute, 72°C for six minutes; 72°C for 
two minutes. IPCR products (5 µL) were gel electrophoresed on a 1% agarose gel 
containing 1´ SYBR Safe DNA Gel Stain and visualised using the LiCor Biosciences 
Odyssey Fc instrument at 600 nm for the presence of a 6.95 kb band (corresponding to 
pSBbi-RP:DTF-I). Due to the small size difference between amplified pSBbi-RP:DTF-I 
DNA and unamplified pSBbi-RP:TF template (6.95 kb and 7.26 kb respectively), IPCR 
products (300 ng) were discriminated by AccI digestion (Table 2.1). pSBbi-RP:DTF-I 
has one AccI restriction site whereas pSBbi-RP:TF has two AccI restriction sites 
(Appendix 3Appendix 4). Following heat inactivation, the samples were gel 
electrophoresed and visualised as mentioned above. Bands corresponding to the size of 
AccI-digested pSBbi-RP:DTF-I (6.95 kb) were excised and purified from the gel (see 
section 2.11). Purified DNA was digested overnight with 10 U of DpnI enzyme to 
degrade any remaining template. Prior to ligation, the DNA was purified (see section 2.9) 
and the 5¢ end was phosphorylated for blunt-end ligation with T4 Polynucleotide Kinase 
(PNK; Thermo Scientific #EK0031) as per manufacturer’s instructions. In brief, a 20 µL 
reaction containing all 15 µL of sample, 10 U of PNK, 2 µL of 10´ T4 PNK Reaction 
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Buffer A and 2 µL of 10 mM ATP (NEB #B0202S) was incubated at 37°C for 20 min. 
The kinase was then inactivated at 75°C for 10 min and DNA was ligated overnight (see 
section 2.12). Ligase was heat inactivated at 65°C for 10 min before the DNA was used 
to transform bacteria.   
 
2.23 Immunostaining for flow cytometry 
All centrifugations were executed at 453 ´g for five minutes at 4°C. For surface staining, 
cells were first washed by centrifugation then resuspended in 0.1% BSA/PBS and kept 
on ice throughout the protocol. Samples were prepared by aliquoting 2 ´ 105 cells into 
each tube then centrifuged. Pelleted cells were resuspended in 100 µL of 2 µg/mL of 
TF8-5G9 antibody, 2 µg/mL of anti-human IL-12 (Table 2.3) or 0.1% BSA/PBS and 
incubated on ice for 15 min. For cold inhibition experiments, TF8-5G9 was incubated 
with 10 µg/mL of TF-Fc (Callaghan Innovation) prior to primary staining. In addition, 
anti-mouse Ig compensation beads (two drops; BD #55284) were stained with 2 µg/mL 
of TF8-5G9 antibody. Cells and beads were washed by centrifugation, resuspended in 
100 µL of 2 µg/mL of anti-mouse-AF488 (Table 2.3) or 0.1% BSA/PBS and incubated 
on ice, in the dark, for 15 min. Cells and beads were finally washed by centrifugation, 
resuspended in 500 µL of 0.1% BSA/PBS and stored on ice, in the dark until flow 
cytometric analysis. For intracellular staining, cells were fixed in 200 µL of flow 
cytometry fixation buffer prior to staining. Antibody dilutions were prepared in 
permeabilisation buffer and cells were stained as per the surface group.  
 
2.24 Flow cytometry 
Sample acquisition of stained, unstained, single stained, compensation and isotype 
stained cells was performed using a BD LSRFortessa flow cytometer with the BD 
FACSDiva software. Voltages were set using unstained and single stained cells. For all 
samples, 10,000 events were acquired. Using FlowJo software version 10.5, data were 
subjected to forward scatter (FSc) and side scatter (SSc) doublet discrimination prior to 




2.25 Preparation of lysate from cell culture 
Protein lysates were prepared by adding 1 ´ 107 cells (EL4 or EL4 transfectants; Table 
2.5) to 120 µL of cell lysis buffer followed by 30 minutes incubation on ice. The samples 
were centrifuged at 16,000 ´g for one minute, pellets were discarded and concentration 
of the supernatant (containing lysate) was measured (see section 2.26 below). Lysates 
were then stored at -80°C. 
 
2.26 Bicinchoninic acid assay (BCA) for protein lysate quantification  
Protein concentrations were measured following the microplate procedure of the Pierce 
BCA Protein Assay Kit (Thermo Scientific #23227). In brief, a working reagent of 50 
parts of “BCA Reagent A” with 1 part of “BCA Reagent B” was prepared. A BSA protein 
standard was prepared in doubling dilutions from 2 mg/mL to 0.0625 mg/mL. Protein 
sample or BSA standard (10 µL) was added to a 96-well flat-bottom clear plate in 
duplicate then 200 µL of working reagent was added to each well. The plate was 
incubated at 37°C in the dark for 30 min. Absorbance was measured on a microplate 
reader at 562 nm and data were analysed using GraphPad Prism 7 software. Protein 
concentrations were determined by comparing each unknown sample to the standard 
curve. 
 
2.27 Western blot analysis 
EL4 cell lysates (10 µg) or soluble TF-Fc (1 µg) samples were resuspended in 15 µL of 
PBS and added to 5 µL of 4´ Bolt LDS Sample Buffer. For samples to be boiled/reduced, 
10 µg of samples were resuspended in 13 µL of PBS and supplemented with 5 µL of 4´ 
Bolt LDS Sample Buffer and 2 µL of 10´ Bolt Sample Reducing Agent. Reduced 
samples were then boiled for five minutes and plunged on ice. A 4-12% Bis-Tris gel was 
inserted into an electrophoresis tank (XCell SureLock Mini-Cell; Invitrogen #EI0001) 
and the tank was filled with Bolt MOPS SDS Running Buffer and 0.5 mL of Bolt 
antioxidant. Wells were washed thoroughly before lysate samples (20 µL) and molecular 
weight marker (7 µL) were loaded. The gel was run for 40 minutes at 200 V, 300 mA on 
ice. Proteins were transferred from the gel to a nitrocellulose membrane using the XCell 
II Blot Module (Invitrogen #EI9051). The blot module was placed in an electrophoresis 
tank, filled with Bolt Transfer Buffer and the transfer was run for one hour at 30 V, 400 
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mA on ice. Membranes were submerged in PBS overnight at 4°C to increase the binding 
of the proteins to the membrane. Following overnight incubation, membranes were 
blocked with 1% BSA/PBS for one hour on a rocker then incubated in 1 µg/mL of TF8-
5G9 antibody or anti-b-actin (Table 2.3) antibody diluted in 1% BSA/PBS overnight at 
4°C on a rocker. Membranes were washed in 0.1% Tween20/PBS three times for 15 min 
on a shaker then incubated in a 1/10,000 dilution of anti-mouse-AF680 (Table 2.3) for 
one hour on a rocker and in the dark. Wash steps were performed as described above and 
fluorescently labelled protein was visualised using the LiCor Biosciences Odyssey Fc 
instrument at 600, 700 and 800 nm.  
 
2.28 Fibrin generation assay (FGA) 
EL4 or EL4 transfectants (Table 2.5) were resuspended in PBS at 2500 cells/µL and 20 
µL of each sample was added to 100 µL of PPP in a 96-well flat-bottom clear plate. 
Coagulation was initiated by adding 14 µL of 10 mM of CaCl2 and absorbance was 
immediately measured on a microplate reader at 562 nm. Measurements were taken every 
10 s for 30 min at room temperature. Area under the curve was calculated from the 
initiation point until the timepoint at which the absorbance of the PBS control began to 
rise, indicating triggering of the TF-independent intrinsic coagulation pathway (5% of 
maximum fibrin; ref. [102]). For the blocking experiments, cells were incubated with 20 
µg/mL or 40 µg/mL of either TF8-5G9 antibody or anti-human IgG isotype control 
(Table 2.3) on ice for 30 min prior to addition to the welled-plate. All samples were 
performed in triplicate. 
 
2.29 Overhang PCR 
BsmBI overhang primers (Table 2.2) were used to add BsmBI restriction sites to the full-
length huTF gene. Template DNA (1 ng of pSBbi-RP:TF), 1 µL of 0.5 µM of each 
forward and reverse primer (see Table 2.2), 25 µL of 2´ PCR master mix were mixed 
together and milliQ water was supplemented to reach a total volume of 50 µL. The 
parameters used for overhang PCR were: 95°C for two minutes; 35 cycles of 95°C for 
30 s, 65°C for 30 s, 72°C for one minute per kb; 72°C for five minutes. DNA products 
(5 µL) were gel electrophoresed on a 1% agarose gel containing 1´ SYBR Safe DNA 




2.30 DNA sequencing  
DNA (200 ng) was amplified using 3.2 pmol/5 µL of forward and reverse primers 
respectively and sent to the Genetic Analysis Service by the Department of Anatomy at 
the University of Otago. Sanger sequencing was performed using an ABI 3730xl DNA 
Analyser. 
 
2.31 Descriptive statistics, data analysis and presentation 
DNA sequences were analysed using Geneious 11.1.4 software. A562nm levels measured 
by BCA assay, A405nm levels measured by FGA and A585nm levels measured by resazurin 
assay were analysed in GraphPad Prism 7 (GraphPad, San Diego, CA). Flow cytometric 
data were analysed using FlowJo 10.5 software.  
 





3.0  Results 
 
3.1 Cloning of the full-length human TF gene (huTF) 
For stable and efficient integration of human genes into the genome of murine EL4 cells, 
genes were cloned into Sleeping beauty (SB) transposon vectors for SB-mediated 
transposition. The SB transposon system consists of two plasmids: one encoding the SB 
transposase gene SB100X and the other containing the genes of interest. The SB 
transposase excises the gene of interest flanked by inverted tandem repeats (ITR) and 
inserts gene cassettes at TA-nucleotide sites randomly across the genome of target cells 
[103]. Synthesised gBlock DNA encoding the full-length huTF gene and the bidirectional 
SB vector pSBbi-RP were digested with SfiI. To ensure the correct orientation of cloning, 
the two SfiI sites were asymmetric (Appendix 1). Following digestion, SB vector DNA 
was dephosphorylated to prevent self-ligation. Prior to ligation, digested SB vector and 
huTF insert were subjected to gel electrophoresis and correct DNA band sizes were 
excised and purified (data not shown). E. coli TOP10 were then transformed with ligated 
DNA (pSBbi-RP:TF) and five colonies were subjected to a colony PCR using SB primers 
flanking the SfiI insertion sites (Table 2.2 and Figure 3A). Three colonies displayed the 
correct band size corresponding to the huTF gene insert (996 bp), while two colonies 
displayed band sizes corresponding to the previously inserted gene (1.7 kb), suggesting 
poor SfiI digestion and self-ligation of the vector. Two huTF-positive colonies were 
subjected to Miniprep plasmid amplification and purification for verification by DNA 
sequencing. Sequencing results showed consensus in the huTF gene of both plasmids 







Figure 3: Colony polymerase chain reaction (PCR) and sequencing results for the 
pSBbi-RP:TF plasmid. 
Full-length tissue factor (huTF) gene was cloned into pSBbi-RP (Sleeping beauty; SB) 
plasmid using restriction cloning with SfiI resulting in pSBbi-RP:TF plasmid. (A) Using 
SB primers, colony PCR was performed to screen transformed E. coli colonies (1-5) for 
the presence of the full-length huTF within SfiI sites. Lane MW: 2-log DNA ladder, lanes 
2, 4 and 5: PCR-positive colonies for full-length huTF (996 bp), lane 6: milliQ water 
negative control, lane 7: vector backbone (pSBbi-RP) positive control, lane 8: pSBbi-
RP:nil insert ligation. (B) Sequencing results to verify the positive transformants. 
Plasmids from transformants 2 and 5 were purified by Miniprep plasmid purification and 
sequenced using SB primers. Black bars represent consensus between the huTF gene, 


















3.2 Puromycin selection of untransfected EL4 
Murine EL4 cells are susceptible to the antibiotic puromycin which causes cell death by 
inhibiting protein synthesis [104]. All plasmids used in this research contain the 
puromycin N-acetyltransferase (pac) gene from Streptomyces alboniger, conferring 
resistance to puromycin selection in all transfected cells (Appendix 3 Appendix 6). To 
determine the optimal concentration at which puromycin induces untransfected EL4 cell 
death, EL4 cells were incubated in a titration of the antibiotic from 7.8125 ng/mL to 
8,000 ng/mL or R5 media only (negative control). Resazurin, a weakly fluorescent blue 
dye which is reduced to a highly fluorescent pink chemical by metabolically active cells, 
was used as an indicator of cell viability [105]. Viable cells, which reduce resazurin, 
strongly fluoresce at A585nm whereas dead cells with no metabolic activity produce no 
fluorescence. Resazurin was added during the final four hours of the 72-h incubation 
after which cell viability was quantified by fluorometric analysis. Maximal death of EL4 
cells was sufficiently induced by a puromycin concentration of 2,000 ng/mL, as indicated 
by the lowest level of resazurin fluorescence (Figure 4). Increasing concentrations of 
puromycin beyond this point up to 8,000 ng/mL did not further decrease fluorescence 
levels. Thus 2,000 ng/mL was the optimal cytotoxic concentration of puromycin 
necessary to select out all untransfected EL4 cells and was therefore utilised for 






Figure 4: Determination of the optimal puromycin concentration to induce cell 
death within untransfected EL4 cells. 
EL4 cells were treated with puromycin with a titrating concentration from 7.8125 ng/mL 
to 8000 ng/mL for 72 h (final concentration 1 ´ 105 cells/mL). Resazurin (10%) was 
added at the final four hours and fluorescence was measured using a microplate reader 
(excitation 540 nm / emission 585 nm). Data are expressed as the means of duplicates 
from one optimisation pilot experiment. Error bars represent mean ± SD. 











































3.3 Transfection of EL4 cells with the full-length huTF gene. 
All plasmids used in this research to transfect EL4 contain an RFP reporter gene as an 
indicator for successful transfection (Appendix 3Appendix 4). Transfection of EL4 cells 
with the pSBbi-RP:TF plasmid (Table 2.4 and Figure 3) was carried out using the Neon 
transfection system. To ensure healthy growth, transfected EL4 cells were cultured at an 
increasing concentration of puromycin, from 1 µg/mL to 2 µg/mL at days one and two 
respectively. Images of cells were captured by fluorescence microscopy to observe the 
expression of RFP, using untransfected EL4 to normalise background fluorescence levels 
(Figure 5). Cells emitting red fluorescence represent puromycin-resistant cells 






Figure 5: Microscopy images showing red fluorescent protein (RFP) expression in 
pSBbi-RP:TF transfected EL4 cells.  
Full-length huTF gene was transfected into EL4 from the RFP-expressing plasmid 
pSBbi-RP:TF using the SB transposon and Neon transfection systems. Upright 
fluorescence microscopy with 200´ magnification was used to visualise the cells using 
(A,C) bright-field view or (B, D) fluorescence of the reporter gene RFP. EL4: 
untransfected; EL4-TF: transfected. Scale bar represents 200 µm. Images are 










3.4 Truncation of the full-length huTF gene to D1-106huTF 
To delete the FVII/VIIa binding site from the huTF protein, site-directed mutagenesis of 
the pSBbi-RP:TF plasmid was performed by IPCR. IPCR primers (Table 2.2) were 
designed to bind to pSBbi-RP:TF, flanking the locus of the huTF gene encoding amino 
acids 1-106 (FVII/FVIIa binding sites). Primers annealed in back-to-back orientation, 
amplifying the pSBbi-RP backbone and amino acids 107-219 of the huTF insert. The 
resulting IPCR product consisted of a pSBbi-RP backbone with D1-106huTF insert 
which was re-circularised by blunt-end ligation to form the pSBbi-RP:DTF-I plasmid. A 
schematic diagram of the gene truncation strategy is summarised in Figure 6.  
 
Initially, PCR was performed according to the manufacturer’s instructions for the Q5 
High-fidelity DNA polymerase. However, this approach yielded little to no DNA 
amplification when observed by gel electrophoresis (data not shown). Several studies 
using the IPCR technique on large plasmids, albeit with lower fidelity DNA polymerases, 
have suggested that longer PCR extension times provide more efficient elongation of 
DNA fragments [106, 107]. This approach was tested in the current study by prolonging 
the extension time from 3.5 minutes per cycle to 6 minutes per cycle. Results from the 
optimised method successfully generated DNA which approximately corresponded to the 
size of linearised pSBbi-RP:DTF-I (6.97 kb; Figure 7A). Due to the small difference of 
the DNA fragment removed by IPCR (315 bp), it was difficult to distinguish between gel 
bands from the IPCR-generated and template plasmids (pSBbi-RP:DTF-I and pSBbi-
RP:TF respectively; Figure 7A). Since one of the two AccI sites is located in the deletion 
site and is lost during amplification, we therefore screened for IPCR-positive DNA by 
digesting amplified DNA with AccI (Figure 6Figure 7B). pSBbi-RP:DTF-I plasmids with 
a single AccI restriction site should yield a 6.97 kb linear fragment, while pSBbi-RP:TF 
templates with two AccI restriction sites, produce fragments 5.46 kb and 1.82 kb in length 
(Figure 6, Appendix 3Appendix 4). Following AccI digestion of pSBbi-RP:DTF-I, a 
mixture of amplified and unamplified DNA products corresponding to all three possible 
band sizes was observed. The 6.97 kb band from the AccI digested pSBbi-RP:DTF-I was 







Figure 6: Site-directed mutagenesis of the TF gene by inverse PCR (IPCR). 
IPCR primers (Table 2.2) were used to delete the gene locus of TF that codes for the 
factor VII/VIIa (FVII/FVIIa) binding site. The IPCR primers anneal to the plasmid in 
reverse orientation, flanking the region to be deleted (Appendix 1). DNA amplification 
occurs outwards, excluding this region from the resulting PCR product. The DNA 
product is then re-ligated forming a plasmid with the desired gene deletion. Red sections 






Figure 7: IPCR truncation of the pSBbi-RP:TF plasmid to produce D1-106huTF. 
The full-length huTF gene was truncated to D1-106huTF by performing IPCR on pSBbi-
RP:TF which served as the template for amplification. (A) Using IPCR primers, pSBbi-
RP:TF plasmid was amplified resulting in pSBbi-RP:DTF-I plasmid. Lanes MW: 2-log 
DNA ladder, lanes 1-2: DNA products generated using IPCR primers (6.96 kb), lanes 3-
4: DNA products generated using SB primers positive control (996 bp), lane 5: milliQ 
water negative control, lane 6: vector backbone positive control (pSBbi-RP:TF; 7.28kb). 
(B) Screening to verify IPCR-generated products by AccI digestion. Successfully 
amplified DNA (pSBbi-RP:DTF-I) produces a single band at 6.96 kb. Unamplified DNA 
(pSBbi-RP:TF) produces two bands at 5.46 kb and 1.82 kb. Lanes MW: 2-log DNA 
ladder, lanes 1-2: digestion of IPCR-generated DNA, lanes 3-4: digestion of vector 
backbone (pSBbi-RP:TF) for size comparison.  
 














3.5 Transformation of E. coli Top10 with commercially or IPCR-derived  
D1-106huTF gene 
Due to initial challenges with the IPCR strategy, a synthetic gBlock of the D1-106huTF 
gene was commercially obtained. This gBlock was designed to encode the same 
nucleotide sequence as the D1-106huTF insert of the pSBbi-RP:DTF-I plasmid generated 
by IPCR. As IPCR was optimised prior to the arrival of the gBlock, both forms of the 
mutant D1-106huTF gene (gBlock-derived D1-106huTF and IPCR-truncated D1-
106huTF) were processed in parallel. 
 
The synthetic gBlock DNA encoding the D1-106huTF gene was designed with 
asymmetrical SfiI flanking sites (Appendix 2), identical to the full-length huTF gBlock 
(section 3.1). The D1-106huTF gBlock was cloned into the SB vector pSBbi-RP 
following the identical methods used for the full-length huTF (see section 3.1; Cloning 
of the full-length huTF gene). Both plasmids containing the D1-106huTF insert (pSBbi-
RP:DTF and pSBbi-RP:DTF-I) were used to transform E. coli TOP10. Colony PCR was 
performed using SB primers (Figure 8). Among six pSBbi-RP:DTF transformant 
colonies, three displayed bands approximate to the expected 681 bp D1-106huTF gene 
insert (Figure 8A). Despite the slim size difference observed, DNA sequencing 
confirmed the truncated sequence D1-106huTF gene insert for two colonies (Figure 8C). 
As for pSBbi-RP:DTF-I transformant colonies, all ten colonies displayed the correct band 
sizes corresponding to the D1-106huTF gene insert (Figure 8B; 681 bp). One colony was 
selected for sequencing and results confirmed the D1-106huTF gene insert sequence 
within the pSBbi-RP:DTF-I plasmid (Figure 8C).  
 
Sequencing results revealed one ambiguity in the forward read of the D1-106huTF gene 
of colony 1 pSBbi-RP:DTF plasmids (Figure 8C), identified to be a G/T nucleotide. The 
reverse read of the gene showed full consensus with D1-106huTF and identified the 
ambiguity was a G nucleotide, indicating that a mutation was not introduced. Colonies 3 
(pSBbi-RP:DTF-I) and 5 (pSBbi-RP:DTF) showed full consensus with the D1-106huTF 





Figure 8: Colony PCR and sequencing results for the pSBbi-RP:DTF and 
 pSBbi-RP:DTF-I plasmids. 
Truncated huTF (D1-106huTF) gene was cloned into pSBbi-RP plasmid using SfiI 
restriction cloning or generated by IPCR, resulting in pSBbi-RP:DTF or pSBbi-RP:DTF-
I plasmids respectively. Using SB primers, colony PCR was performed to screen E. coli 
colonies transformed with either plasmid. Truncated huTF band (681 bp) was detected 
in selected colonies (A) 1, 3, and 5, transformed with pSBbi-RP:DTF and (B) 1-10, 
transformed with pSBbi-RP:DTF-I plasmids. Lanes MW: 2-log DNA ladder; pSBbi-
RP:nil insert ligation negative control: lanes 7, 8 (for A) and 12 (for B); vector backbone 
(pSBbi-RP) positive control: lanes 9 and 11 (for A and B respectively); milliQ water 
negative control: lanes 10 and 12 (for A and B respectively). (C) Sequencing results to 
verify selected positive transformants. Plasmids from transformants 1 and 5 in figure A 
and transformant 3 in figure B were purified by Miniprep plasmid purification and 
sequenced using SB primers. Black bars represent consensus between the D1-106huTF 
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3.6 Transfection of EL4 cells with the D1-106huTF gene.  
Transfection of EL4 cells with the pSBbi-RP:DTF and pSBbi-RP:DTF-I plasmids (Table 
2.4) was carried out using the Neon transfection system. The transfection and selection 
were carried out following the identical methods used for the full-length huTF (see 
section 3.3; Transfection of EL4 cells with the full-length huTF gene). Fluorescence 
microscopy images of transfected cells showed that the majority of EL4-TF and EL4-
DTF transfectants appeared to express RFP while only some EL4-DTF-I transfectants 
expressed RFP (Figure 9). This observation was later quantified by flow cytometric 




Figure 9: Microscopy images showing RFP expression in pSBbi-RP:TF,  
pSBbi-RP:DTF, or pSBbi-RP:DTF-I transfected EL4 cells. 
Full-length or truncated huTF gene was transfected into EL4 from the RFP-expressing 
plasmids pSBbi-RP:DTF and pSBbi-RP:DTF-I using the SB transposon and Neon 
transfection systems. Upright fluorescence microscopy with 200´ magnification was 
used to visualise and compare the cells using (A, C, E, G) bright-field view or (B, D, F, 
H) fluorescence of the reporter gene RFP. EL4: untransfected; EL4-TF: transfected with 
full-length TF; EL4-DTF: transfected with truncated huTF; EL4-DTF-I: transfected with 

















3.7 Expression of TF in EL4 transfected with pSBbi-RP:TF, pSBbi-RP:DTF or 
pSBbi-RP:DTF-I  
To confirm the ability of transfected cells to express full-length or truncated TF, we 
analysed the surface and intracellular expression of TF by flow cytometry (Figure 10A). 
Cells were stained for TF using the anti-TF antibody TF8-5G9. EL4-TF cells exhibited 
high levels of surface expressed TF. The corresponding RFP expression profile in EL4-
TF showed equivalently high expression of fluorescence genes (Figure 10B), consistent 
with the images of the cells captured by fluorescence microscopy (Figure 9D). 
 
EL4-DTF cells exhibited no detectable surface expressed TF. This was in contrast to the 
high RFP expression of EL4-DTF cells (Figure 9F and Figure 10B). Surprisingly, EL4-
DTF-I cells exhibited low levels of surface expressed TF (Figure 10A), despite 
deficiencies in RFP gene expression that were observed by both fluorescence microscopy 
and flow cytometric analysis (Figure 9H andFigure 10B). 
 
To determine whether TF expression was being limited to the intracellular environment, 
cells were fixed and permeabilised to facilitate the access of detection antibodies to the 
intracellular level of the cells. TF expression in permeabilised cells was highest in EL4-
TF cells and lowest in EL4-DTF-I with EL4-DTF cells as intermediary (Figure 10A). 
Mirroring observations made from images in Figure 9, RFP expression of EL4-DTF-I 
cells was downregulated compared to EL4-TF and EL4-DTF cells. TF and RFP 
expression was directly proportional in these cells; TF-positive cells were RFP-positive, 
TF-negative cells were RFP-negative (Appendix 7). 
 
To further confirm that truncated TF was present in EL4-DTF and EL4-DTF-I cells, we 
performed western blot analyses on whole cell lysates (Figure 11A). Lysates were stained 
for TF using the anti-TF antibody TF8-5G9. Since the extracellular domain of TF has 
three potential glycosylation sites, the molecular weight of TF can vary from around  
35 kDa to anywhere upwards of 47 kDa [108]. The results showed low but detectable TF 
expression in EL4-TF cells, within the range of glycosylated TF, but not in EL4-DTF nor 
EL4-DTF-I cells. Cellular TF was only detectable by TF8-5G9 in the native state (non-
boiled/non-reduced) whereas soluble TF-Fc was detectable in both native and denatured 
states. Differences in the molecular weight of cellular TF and soluble TF are due to 
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conjugation with Fc (26 kDa). Since EL4-TF cells were previously shown to express 
high levels of TF (Figure 10A), the presence of only a weak band for TF demonstrated a 
reduced sensitivity of the western blot assay for antigen detection using the TF8-5G9 






Figure 10: Analysis of TF expression level between EL4 transfectants using flow 
cytometry. 
Flow cytometry was used for the detection of TF in untransfected EL4, EL4-TF, EL4-
DTF and EL4-DTF-I using surface and intracellular staining. (A) Cells were incubated 
with a mouse anti-human TF antibody (TF8-5G9; αTF) and detected using the secondary 
antibody anti-mouse IgG-Alexa Fluor 488 (AF488). For negative controls, cells were 
incubated with secondary antibody only, pre-incubated αTF with TF-Fc (cold inhibition), 
or with TF-Fc alone. For intracellular detection, cells were treated with fix buffer prior 
to staining and antibodies were prepared in permeabilisation buffer. (B) RFP expression 






Figure 11: Detection of full-length or truncated huTF in EL4 cell lysates by western 
blot. 
(A) Boiled/reduced (+) or non-boiled/non-reduced (-) whole cell lysates (20 µg) were 
subjected to polyacrylamide gel electrophoresis (PAGE) and western blotted using 
mouse anti-human TF antibody (clone TF8-5G9) or anti-mouse β-actin IgG, both 
detected with anti-mouse IgG-AF680 (Lanes 1-8). Detectable TF band (Lane 3) is 
indicated by the red arrow. (B) Soluble TF-Fc (1 µg) was used as a positive control 
(Lanes 9 and 10). Results are representative of three experiments. 
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3.8 The procoagulant activity of transfected EL4 cells 
We next determined the procoagulant potential of all four EL4 cell types (EL4, EL4-TF, 
EL4-DTF, and EL4-DTF-I) using a fibrin generation assay (FGA; Figure 12A). FGA 
measures plasma clot turbidity, determined by the rate of fibrin deposition, as an indicator 
of functional coagulant activity. EL4-TF cells were significantly more procoagulant than 
their untransfected cell of origin (EL4) whereas EL4-DTF and EL4-DTF-I failed to 
induce any detectable fibrin (Figure 12A).  
 
To confirm that the procoagulant activity of EL4-TF cells was driven by TF, we tested 
cells with a titrating dose of the anti-TF antibody TF8-5G9 (Figure 12B). Fibrin 
deposition of cells was significantly supressed when blocked with either concentration 
of the antibody (20 µg/mL or 40 µg/mL). Equivalent concentrations of a monoclonal 
mouse IgG control failed to inhibit the FGA. 
 
The importance of the TF-FVII interaction for initiating the extrinsic pathway was tested 
by comparing the activity of procoagulant EL4-TF cells in FVII-depleted (FVII-) plasma 
versus standard plasma (Figure 12C). Since FVII is critical for initiating the TF-driven 
extrinsic pathway, fibrin generation was significantly suppressed by removal of this 







Figure 12: Fibrin generation assays (FGA) comparing transfected EL4 cells. 
Cells (50,000) were added to platelet-poor plasma (PPP) and calcium chloride was 
supplemented to initiate coagulation. Fibrin generation was monitored at 405 nm until 
the negative control (PBS) started to generate detectable fibrin. (A) FGA of EL4, EL4-
TF, EL4-Δ, EL4-ΔI cells. (B) FGA of EL4-TF with inclusion of 20 μg/mL or 40 μg/mL 
of aTF	antibody (TF8-5G9) or IgG isotype control. (C) FGA of EL4-TF using factor 
VII-depleted plasma (FVII- PPP) and standard PPP (Ctrl). One-way ANOVA with 
Bonferroni multiple comparisons test performed on the area under the curves (AUC): ns 
= not significant, ***P < 0.0001 ****P < 0.0001. Error bars represent mean ± SD. 
Samples were loaded in triplicates. Results are representative of three experiments (for 
A and B); experiment performed once (for C).  
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3.9 Development of the antigen expression system for TF8-5G9 CAR cytotoxicity 
assays 
Since the purpose of the truncated antigen model is to be compatible with TF8-5G9 
CARs, it is critical to ensure that cells expressing the antigen are capable of inducing 
anti-TF T cell responses. A luciferase-based cytotoxicity assay was proposed involving 
co-expression of the luciferase reporter gene in target tumour cells. In active, ATP-
producing cells, luciferase oxidises its substrate luciferin and emits a luminescent signal 
[109]. Upon cell death when intracellular ATP is no longer available, the luminescent 
signal is lost [110]. In this manner, tumour cell lines which co-express TF antigen and 
luciferase can be challenged with TF8-5G9 CAR-expressing peripheral blood 
mononuclear cells, allowing cytotoxic activity to be detected as a decrease in 
bioluminescence. 
 
For optimisation of the cytotoxicity assay, the platform was initially developed using the 
unaltered full-length TF antigen. This could later be used as a control to compare the 
cytotoxic activity of TF8-5G9 CAR T cells against truncated TF versus full-length TF. 
To facilitate the co-transfection of the huTF gene with the luciferase reporter gene (luc) 
using a single vector, huTF was cloned into pSBbi-BsmBI by Golden Gate assembly. 
Firstly, BsmBI overhang primers were designed to bind to huTF and create overhangs 
which contain BsmBI restriction sites. BsmBI is a type IIS restriction enzyme which 
cleaves DNA at a site separate to the recognition sequence, leaving overhangs which 
directly assemble to the plasmid [111]. In this way, BsmBI digestion cleaves recognition 
sites from the final DNA product, allowing scarless cloning of the huTF gene into pSBbi-
BsmBI (pSBbi-BsmBI:TF). A schematic diagram of the Golden Gate cloning strategy is 
summarised in Figure 13.  
 
gBlock DNA encoding the huTF gene was cloned into the BsmBI restriction sites of the 
plasmid, upstream of a P2A coding sequence derived from Porcine teschovirus-1. The 
P2A “self-cleaving” peptide facilitates the translation of two separate polypeptides from 
one mRNA transcript through a conserved sequence at the C-terminus which creates 
steric hindrance, causing ribosome skipping or fall-off [112, 113]. P2A was thus used to 
mediate the simultaneous expression and cleavage of the upstream huTF and downstream 
pac resistance genes. E. coli TOP10 were transformed with ligated DNA (pSBbi-
BsmBI:TF) and seven colonies were subjected to a colony PCR using GOI2 primers 
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(Table 2.2) flanking BsmBI insertion sites (Figure 14A). All seven colonies displayed 
correct band sizes corresponding to the amplified region containing the huTF gene insert 
(943 bp). Three huTF-positive colonies were subjected to amplification and purification 
for verification by DNA sequencing.  
 
Sequencing results revealed an ambiguity in the huTF gene of colony 1 pSBbi-BsmBI:TF 
plasmids (Figure 14B), identified as a pyrimidine (C/T) by both the forward and reverse 
reads of the sequence. When aligned to the reference sequence, the original base was 
shown into be a T nucleotide. In addition to this, non-consensus in the murine Igk signal 
sequence was detected, likely as result of errors incorporated when nearing the maximum 
read length. As we could not verify that the huTF sequence of the plasmid DNA matched 
the reference huTF sequence, plasmids from this colony were not chosen for further 
work. Purified plasmids from colony 3 showed full consensus with the huTF gene, 
indicating no mutations were introduced. In colony 5-purified plasmids, a mutation was 
identified in the huTF sequence, indicating a transition from the purine nucleotide A to 
G. Due to redundancy in the genetic code, this mutation did not cause a change in the 
amino acid sequence of the protein produced (GCA to GCG). However, since plasmids 
from colony 3 were identified to be mutation-free, we continued the cloning strategy 
using these plasmids as the backbone for insertion of a second gene, luc, and excluded 
colony 5-purified plasmids from further work.  
 
To obtain the luc insert, plasmid DNA encoding the luc gene was digested with SfiI and 
subjected to gel electrophoresis. Bands corresponding to the size of the luc insert (1.8 kb) 
were excised and purified from the gel. pSBbi-BsmBI:TF plasmids purified from colony 
3 (Figure 14) were SfiI digested and subjected to gel electrophoresis. Bands 
corresponding to the size of backbone DNA (6.6 kb) were excised for ligation. The luc 
insert was cloned into the asymmetric SfiI sites of the pSBbi-BsmBI:TF resulting in the 
pSBbi-BsmBI:TF+luc plasmid which encodes two transgenes: the huTF antigen and 
luciferase reporter. E. coli TOP10 were transformed with ligated DNA (pSBbi-
BsmBI:TF+luc) and a colony PCR was performed using SB primers to amplify the luc 
insert (Figure 15A). All four selected colonies displayed band sizes corresponding to the 
luc gene insert (1.8 bp). Concurrently, DNA from the selected colonies was amplified 
with GOI2 primers to verify the presence of huTF within the same plasmids. All four 
colonies displayed band sizes corresponding to the huTF gene insert, confirming that luc 
and huTF genes were co-expressed within the same plasmid. All luc-positive colonies 
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were plasmid purified for verification by DNA sequencing. Sequencing results revealed 
no mutations in the luc gene of any plasmid (Figure 15B).  
 
Due to time restrictions, transfection of the pSBbi-BsmBI:TF+luc construct in to tumour 






Figure 13: Overhang PCR with BsmBI restriction sites for Golden Gate assembly 
of huTF into a SB transposon vector. 
Primers to amplify the huTF gene were designed with overhang regions containing 
BsmBI restriction sites (BsmBI overhang primers; Table 2.2). BsmBI cleaves at a 
separate site to the recognition sequence and removes the restriction site from digested 
DNA products. The overhangs produced by BsmBI digestion are designed to be 
complementary between the insert and plasmid, allowing seamless assembly of the huTF 






Figure 14: Colony PCR and sequencing results for the pSBbi-BsmBI:TF plasmid. 
Full-length huTF gene was cloned into pSBbi-BsmBI plasmid using restriction cloning 
with BsmBI resulting in pSBbi-BsmBI:TF plasmid. (A) Using gene of interest 2 (GOI2) 
primers, colony PCR was performed to screen transformed E. coli colonies (1-7) for the 
presence of the full-length huTF within BsmBI sites. Lanes MW: 2-log DNA ladder, 
lanes 1-7: PCR-positive colonies for huTF (943 bp), lane 8: pSBbi-BsmBI:nil insert 
ligation negative control, lane 9: vector backbone (pSBbi-BsmBI) negative control , lane 
10: milliQ water negative control. (B) Sequencing results to verify the positive 
transformants. Plasmids from transformants 1, 3 and 5 were purified by Miniprep 
plasmid purification and sequenced using GOI2 primers. Black bars represent consensus 
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Figure 15: Colony PCR and sequencing results for the pSBbi-BsmBI:TF+luc 
plasmid. 
Luciferase (luc) gene was cloned into pSBbi-BsmBI:TF using restriction cloning with 
SfiI resulting in pSBbi-BsmBI:TF+luc plasmid. (A) Using SB and GOI2 primers, colony 
PCR was performed to screen transformed E. coli colonies (1-4) for the presence of luc 
gene within SfiI sites and huTF gene within BsmBI sites, respectively. Lane MW: 2-log 
DNA ladder; lanes 1-4: luc-positive colonies (1.8 kb); lanes 1-4: huTF-positive colonies 
(943 bp); lane 5: pSBbi-BsmBI:TF:nil insert ligation negative control; lane 6: vector 
backbone (pSBbi-BsmBI) negative control; lane 7: milliQ water negative control. (B) 
Sequencing results to verify the positive transformants. Plasmids from colonies 1-4 were 
purified by Miniprep plasmid purification and sequenced using SB primers. Black bars 
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4.0  Discussion 
 
 Discussion 
Rapid innovations in the field of immunotherapy have brought forth a myriad of novel 
treatments to the clinic [17, 58, 114]. Thus far, two of the most successful strategies, 
immune checkpoint inhibitors and CAR T cell therapy, have both focused on engaging 
the cytotoxic actions of T lymphocytes [24]. In haematological cancers, CARs have 
demonstrated durable responses in a broad group of patients; however, widespread 
application of CAR T cell therapy continues to be marred by their limited success against 
solid epithelial cancers, as well as concerns for patient safety [41, 49, 53, 59]. 
Appropriate choice of a specific, targetable antigen is one of the defining factors for 
limiting on-tumour, off-target effects and delivering successful/safe CAR therapy [55]. 
However, in epithelial cancers, most tumour antigens expressed are derived from self-
proteins, usually expressed at other sites around the body on healthy tissues [50]. Clinical 
trials for CARs against solid tumours have been met with severe cases of adverse side 
effects alongside instances of patient fatality [59, 115]. In this regard, it would be useful 
to explore other potential targets or features which may more easily distinguish cancerous 
cells from healthy tissue. 
 
In this research, we presented TF as a novel target antigen for solid cancer 
immunotherapy and developed the foundations for preclinical testing. We aimed to 
address the hypercoagulant nature of TF in vivo by truncating the antigen to remove the 
catalytic FVII/FVIIa binding sites which induce coagulative pathways. This was carried 
out by deleting the gene locus of FVII/FVIIa binding sites encoded within the huTF gene 
using IPCR. 
 
Site-directed mutagenesis by IPCR was initially favoured for its relatively rapid 
execution and taken as an opportunity to explore an alternative mutagenesis technique 
for SB plasmids (previously untested in the McLellan laboratory; ref. [106]). However, 
the failure of this method to produce reliable amplification suggested an incompatibility 
with the plasmid (Figure 6). Previous work in the McLellan laboratory has shown that 
SB plasmids were poorly compatible with another PCR mutagenesis technique, quick-
change PCR. The SB plasmids used in this research contained AT-rich regions, 
particularly at the ITR sites which approached nearly 70% AT-content. AT-rich 
 
 62 
sequences are known to be difficult to amplify by PCR owing to the thermodynamic 
instability of this base pairing [116, 117]. Traditionally, this can be compensated for by 
lowering primer annealing and extension temperatures; however, this comes at the cost 
of compromising the quality of amplified DNA [117-119]. We trialled multiple 
conditions to optimise the protocol and found that prolonged extension time was crucial 
for successful amplification (data not shown). Consequently, this resulted in an increased 
chance of error-prone replication which could alter the desired PCR product.  
 
Throughout this research, we observed defective expression of the RFP reporter in EL4-
DTF-I mutants, both by fluorescence microscopy and flow cytometric analysis (Figure 9 
and Figure 10). Since the transfectants had been subjected to puromycin selection, all 
imaged cells were known to be expressing the pac gene and hence, were successfully 
transfected with pSBbi-RP:DTF-I expression plasmids containing the D1-106huTF gene. 
Flow cytometric analysis revealed a wide range of RFP expression within EL4-DTF-I 
cells, correlating with the range of TF expressed by intracellularly stained populations 
(Appendix 7). This suggested proportional expression of the transgenes encoded in the 
plasmid; i.e RFP-high populations were TF-positive, RFP-low populations were TF-
negative. These results indicated that mutations were likely to have been introduced into 
the RFP gene of the plasmid during amplification by IPCR, potentially causing a 
frameshift. Another explanation for poor RFP expression may have been low transfection 
efficiency which results in downregulated transgene expression. Sequencing of the RFP 
gene could have been performed to confirm the presence of mutations; however, error-
prone replication would most likely have affected regions of the plasmid other than the 
reporter gene. Therefore, a more favourable approach would have been to clone the 
sequenced D1-106huTF gene into a new SB backbone (pSBbi-RP) using SfiI restriction 
sites.  
 
Alternatively, the truncated huTF gene could have been generated by a traditional PCR 
approach. Primers could be designed to amplify an insert region encoding amino acids 
107-219 of the huTF gene in pSBbi-RP:TF. Amplification of a shorter DNA fragment 
would reduce the likelihood of mutations being introduced; however, this would require 
the addition of restriction sites flanking the insert to facilitate cloning back in the plasmid. 
Scarless cloning would be desirable to prevent the introduction of excess base pairs 
between the signal sequence and the protein coding region of the gene which could affect 
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the ability of the protein to surface express. For this, a Golden Gate cloning approach 
similar to the one described in Figure 13 could be taken. 
 
To facilitate the transduction of gene cassettes into the murine genome, the SB-
transposase system was utilised. Traditional viral delivery methods, such as retroviral 
and lentiviral systems, promote high transduction efficiency and sustained gene 
expression; however, these have several major drawbacks [120]. Viral vectors show high 
preference for insertion into gene encoding regions and thus, can disrupt recipient host 
cell functions and elicit unwanted adverse effects [121]. Additionally, viral vectors are 
restricted by the size of DNA they may carry, have associated immunogenicity and 
carcinogenicity and are costly to purify [122]. By comparison, SB-mediated non-viral 
delivery methods are cheaper, relatively safe and have the capacity to transfer larger 
genes [123]. Initially, non-viral modes such as SB plasmid-based delivery had reduced 
transduction efficiency compared to viral delivery systems [120]. This has since been 
overcome through the engineering of SB transposases into more hyperactive variants 
such as the SB100X which was used in this research [120]. Risk of insertion into 
transcriptionally active sites remains possible; however, SB transposase systems have 
been shown to integrate more randomly than all vectors currently in use for gene therapy 
and therefore convey better safety from adverse events [120, 124, 125]. Following 
integration into recipient genomes, the potential for remobilisation of transposons is low 
[120]. Additionally, reintegration remains relatively random and is no more likely to 
disrupt active genes than the original insertion [120]. SB was chosen for this study to 
facilitate the expression of multiple genes; ampicillin resistance, required for selection of 
positive-transformants, pac resistance, required for selection of positive-transfectants 
and crucially, the RFP reporter gene, which in this research was the crucial feature 
illustrating the problems encountered throughout execution.  
 
In consultation with Dr Yoshio Nakatani (Structural Biologist; Department of 
Microbiology and Immunology, University of Otago), threonine-106 in the interdomain 
strand was proposed to be the optimal site for truncation. The disordered linker strand 
separates the protein modules comprising the extracellular domain of TF and by nature, 
is not involved in tertiary structures of either module. The rationale for this truncation 
site was four-fold:  
1. To conserve the conformation of the C-terminal module such that translocation 
of truncated protein to the cell surface would not be disrupted 
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2. To remove the majority of interactions involved in FVII-FVIIa binding, including 
two out of three of the most energetically important residues; lysine-20 and 
isoleucine-22 
3. To retain the binding epitope for activation of a TF8-5G9 CAR 
4.  To mitigate the chance for spontaneous tumour rejection in mice by removing 
the maximal amount of immunogenic material 
 
Flow cytometric analysis detected surface expression of truncated-TF by EL4-DTF-I 
cells at comparatively low-levels to the full-length expressing cell line EL4-TF, whereas 
TF expression was completely undetectable in the gBlock mutant EL4-DTF cells (Figure 
10A). It is possible that low/nil-detection resulted from lack of surface expressed protein. 
When cells were intracellularly stained, higher levels of the antigen could be detected, 
suggesting that truncated protein was being produced in the endoplasmic reticulum (ER) 
but protein folding had been compromised by truncation. Alternatively, low/nil-detection 
may have been observed if truncated antigen was surface expressed, but the conformation 
of the antigen was no longer compatible with the TF-detection antibody, TF8-5G9. 
Equally in both cases, lack of targetable antigen does not fulfil the purposes of this 
antigen model. 
 
Although there was a minor shift in TF fluorescence once cells were fixed and 
permeabilised, previous work in the McLellan laboratory has never shown EL4 cells to 
be procoagulant or express TF. This shift was therefore most likely due to non-specific 
binding of the TF8-5G9 antibody to the intracellular contents of EL4 cells. An IgG1 
isotype control was included in these experiments to determine the influence of non-
specific binding; however, this showed more reactivity with intracellular components 
than the TF8-5G9 detection antibody once cells were fixed and permeabilised (data not 
shown). We concluded that the isotype control used did not accurately reflect the 
background non-specific staining levels of TF8-5G9 and therefore, was not an 
appropriate control. Single staining with anti-mouse-AF488 and cold inhibition of TF8-
5G9 were determined to be more relevant negative controls for these experiments. 
 
Reasons for the differences in the level of surface expressed antigen between EL4-DTF 
and EL4-DTF-I are not entirely clear, despite both cell lines expressing identical D1-
106huTF sequences. This finding was particularly surprising as the IPCR-derived 
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mutants EL4-DTF-I cells simultaneously demonstrated superior surface expression of 
antigen while expressing defects in reporter gene function which may reflect 
abnormalities in the plasmid (Figure 9Figure 10). We theorise that lack of surface 
expression of truncated TF may have been due to a bottleneck effect, caused by the 
overexpression of loose or slow folding protein. Unaffected pSBbi-RP:DTF plasmids 
may have allowed for overproduction of the truncated TF. Due to folding difficulties, the 
efficiency of processing the truncated protein may have been compromised, overloading 
the ER with misfolded protein [126]. In this manner, enzymes and components recruited 
in processing and transport of proteins from the ER to the surface membrane may have 
been fully saturated, preventing the translocation of any mature forms of truncated 
protein that may have been present. Paradoxically, mutations to pSBbi-RP:DTF-I 
plasmids affecting transgene expression levels, could have allowed for a lower 
production of truncated protein. Without the oversaturation of proteins at the ER, 
complete folding and processing into mature protein may have been allowed to occur, 
thereby permitting surface expression of truncated antigen.  
 
In conjunction with flow cytometric analysis, western blotting was carried out using the 
TF8-5G9 antibody to detect TF production in cell lines transfected with the truncated D1-
106huTF gene (Figure 11). Despite strong expression of TF observed by flow cytometry, 
only a weak band was detected in the strongly TF-positive cell line EL4-TF. Given this 
discrepancy, we determined that the poorly detectable TF band represented a reduced 
sensitivity of the western blot assay for detection of TF. Though TF-Fc was strongly 
detectable with TF8-5G9, variations in protein processing and post-translational 
modifications (e.g glycosylation of the extracellular domain) in the cell-associated TF 
may have affected the affinity of the antibody for TF antigen. Other studies which have 
used TF8-5G9 to detect TF by western blot have coupled the antibody to beads or 
substrates which increase the affinity of binding [127, 128]. Additionally, cellular TF 
was detectable only in the native state. This showed that antibody binding was dependent 
on protein conformation, which was likely to be altered in truncated TF. Absence of 
bands in EL4-DTF and EL4-DTF-I lysates were therefore attributed to the presence of 
TF at levels below the detectable limit, as opposed to a lack of TF production by EL4-
DTF and EL4-DTF-I cells. The TF8-5G9 antibody had not previously been tested in the 
McLellan laboratory for western blot assays and from these results, we concluded that 
direct use of this antibody for western blot analysis was not compatible. Flow cytometry 
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was determined to be a more accurate indicator of TF expression and results from this 
assay were deemed inconclusive. 
 
The procoagulant activity of each cell type was assessed by a functional FGA (Figure 
12A). Neither cell line transfected with truncated TF expressed coagulative ability 
compared to their cell of origin EL4. Combined with observations from flow cytometric 
analysis, this was perhaps the most significant finding from this research. Since EL4-
DTF cells had not been shown to surface express TF, these cells were not expected to 
have coagulant activity. Strikingly, since EL4-DTF-I cells had been identified to express 
low levels of TF and did not induce coagulation, these results showed that the coagulative 
function of any surface expressed antigen had been effectively abolished. Despite low 
surface expression levels, previous studies have demonstrated that low molar 
concentrations of TF (3 - 10 molecules per µm2) are sufficient to induce fibrin deposition 
[129, 130]. Previous work in our laboratory has shown that apoptotic vesicles expressing 
TF at levels undetectable by flow cytometry, demonstrate potent coagulative activity 
when measured using the same functional assay [102].  
 
Blocking experiments were performed with only the cell type which exhibited 
procoagulant function, EL4-TF (Figure 12B). Pre-incubation with TF8-5G9 significantly 
delayed the onset of fibrin generation but did not completely inhibit the FGA. Given the 
potency of TF, the concentrations of antibody chosen and incubation times may not have 
been sufficient to saturate the binding sites which inhibit the interaction with subsequent 
coagulation factors. Additionally cells were blocked with another anti-TF antibody; 
however, TF8-5G9 proved to be a superior inhibitor of procoagulant activity (data not 
shown). This observation was consistent with previous works and validated the choice 
of antibody to be used as structural basis of a novel CAR design. Similarly, removal of 
the FVII ligand from the FGA neutralised the procoagulant function of TF by restricting 
formation of the catalytic complex (Figure 12C). Whilst fibrin generation was not 
completely abrogated, the supplier does not guarantee 100% removal from plasma and 
therefore, up to 1% of residual FVII may have remained present to activate extrinsic 




 Future work 
Preliminary work for the development of a truncated TF antigen was carried out on 
murine TF-negative EL4. This was necessary to optimise the expression of the truncated 
antigen and characterise the coagulant activity of the cells. However, EL4 cells are 
derived from murine T cell lymphoma and therefore, do not constitute a classical solid 
tumour model. Once the truncated TF antigen has been optimised, future work should 
continue in a solid cancer cell line such as B16 melanoma. B16 expresses murine TF and 
is a well-established, readily transplantable tumour model [131]. The cumulative effects 
of expressing truncated human TF and the murine TF should be assessed for safety.  
 
The point of truncation chosen appears to address our initial aim to remove the 
coagulative function of the antigen. However, results from this research did not 
demonstrate that truncated TF could be reliably surface expressed, warranting further 
optimisation to stably express the mutant protein. In this regard, generating a protein 
crystal structure may be an effective way of analysing the folding or  misfolding of the 
truncated protein and characterise binding capacity with FVII/FVIIa and TF8-5G9. It 
may be desirable to explore other truncation sites which impart less effect of protein 
conformation. Alternative approaches to protein truncation which may neutralise the 
procoagulant effects of human TF in murine models would be to generate knock-in 
mouse models or use immunodeficient mice. Replacing the expression of murine TF with 
human TF is advantageous in providing a way to examine on-target, off-tumour effects. 
Immunosuppressed mice such as NSG model would allow transplantation of human 
tumour cells, displaying physiological levels of antigen which more accurately reflect 
the disease state.  
 
Due to time constraints we were not able to optimise the truncated antigen nor complete 
the necessary framework for the development of cytotoxicity assays. The BsmBI cloning 
strategy performed in this research provides a scaffold for future in vitro cytotoxicity 
assays that will enable optimisation of TF8-5G9 CARs. The finishing steps in developing 
this assay include transfection of the pSBbi-BsmBI:TF+luc plasmid into EL4 and 
optimisation of the assay, firstly with the full-length antigen. The cloning procedures 




 Concluding remarks 
In this research, a truncated form of TF was generated for future in vivo testing of a TF8-
5G9 anti-TF CAR. Two forms of the truncated huTF gene were compared; an IPCR-
derived mutant and a commercially manufactured gBlock mutant. Cells transfected with 
IPCR-derived TF (EL4-DTF-I) had defective RFP expression but strikingly, displayed 
low levels of surface expressed TF that was functionally inactive. By comparison, cells 
transfected with gBlock-derived TF (EL4-DTF) expressed no surface detectable antigen 
despite having high RFP expression, suggestive of high transfection efficiency. These 
preliminary findings warrant further work to optimise surface expression of the truncated 
antigen. The efficiency of TF8-5G9 CARs can then be tested against the full-length or 
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Appendix 3: Plasmid map of pSBbi-RP:TF 
 
 









Appendix 5: Plasmid map of pSBbi-BsmBI:TF 
 
 
Appendix 6: Plasmid map of pSBbi-BsmBI:TF+luc 
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